查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1138345

全球深部脑刺激器市场-2022-2029

Global Deep Brain Stimulation Devices Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

研发计划的增加、由于神经系统疾病的流行导致对深部脑刺激设备的需求不断增加、政府资金的增加以及对这些设备的认识不断提高，这些都在预测期内推动了市场的增长。

预计对深部脑刺激产品的需求不断增长将推动市场增长。

市场受到对深部脑刺激产品不断增长的需求的推动。其中包括接受深部脑刺激 (DBS) 神经外科手术的人数增加，以及癫痫和帕金森病等神经系统疾病的患病率增加。根据 Andres M. Lozano 等人 2019 年发表在 Nature Reviews Neurology Journal 上的一项研究，全球约有 160,000 名患者接受深部脑刺激来治疗神经和非神经疾病，而且这个数字每年都在增加。预计。癫痫是最常见的神经系统疾病。根据世界卫生组织 (WHO) 的统计，全世界约有 5000 万人患有癫痫症。根据帕金森基金会的数据，全世界有超过 1000 万人患有帕金森病 (PD)。女性比男性更常见。

新产品的推出和批准的增加将刺激市场增长。例如，2019 年 2 月，美敦力 (Medtronic) plc 推出了用于治疗难治性癫痫的深部脑刺激 (DBS)。它向大脑中称为丘脑前核 (ANT) 的目标提供受控的电脉衝。

2019 年 1 月，波士顿科学公司推出了 Verse 原代细胞 (PC) 和 Verse Gevia 深部脑刺激 (DBS) 系统以及 Verse Cartesia Directional Lead。这些系统采用的技术旨在使医生能够控制电刺激的范围、形状、位置和方向，以通过高度个性化的治疗来治疗帕金森病 (PD) 症状。

市场正在见证开发新的深部脑刺激产品的技术进步。例如，2020 年 1 月，雅培实验室宣布，在其 Infinity Deep Brain Stimulation System 中，称为内部苍白球 (GPi) 的大脑区域在运动功能中起关键作用，可以作为 DBS 的目标并得到良好控制它已获得美国 FDA 的扩大批准，包括改善无法治疗的帕金森病症状。它是唯一获准用于治疗运动障碍、帕金森病和特发性震颤的所有主要目标的定向 DBS 系统。该系统通过基于蓝牙无线技术的 iOS 软件平台运行。此外，临床医生可以通过雅培新的 Infirmity Programming 功能简化 iPad mini 设备上的编程过程，从而通过定向引导简化实践并优化患者治疗效果。我可以做到。此外，该系统允许患者使用 Infinity DBS System iPod touch 控制器管理他们的症状。

与深部脑刺激器相关的高成本预计将阻碍市场增长。

预计仪器成本高和与刺激器相关的风险等因素将阻碍预测期内的市场增长。

行业分析

全球深部脑刺激器市场根据波特五力、监管和报销分析、供应链分析、定价分析和未满足的需求等各种行业因素对市场进行了深入分析。

全球深部脑刺激器市场报告提供大约 45 多个市场数据表、40 多个数字和 180 页内容。

内容

第1章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 对深部脑刺激产品的需求增加
    • 限制因素
      • 与这些设备相关的高成本
    • 市场机会
    • 影响分析

第5章行业分析

  • 波特五力分析
  • 监管和报销分析
  • 供应链分析
  • 定价分析
  • 未满足的需求分析

第 6 章按产品类型

  • 单通道深部脑刺激器
  • 双通道深部脑刺激器

第 7 章按应用程序

  • 帕金森病
  • 癫痫
  • 特发性震颤
  • 肌张力障碍
  • 强迫症
  • 其他

第 8 章最终用户

  • 医院
  • 神经科诊所
  • 门诊手术中心
  • 其他

第 9 章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 10 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 按产品类型进行基准测试
  • 值得关注的重点公司列表

第 11 章公司简介

  • 雅培实验室
    • 公司简介
    • 按产品类型划分的产品组合和内容
    • 主要亮点
    • 财务摘要
  • Aleva Neurotherapeutics SA
  • Boston Scientific Corporation
  • Medtronic Plc
  • NeuroPace Inc.
  • Nevro Corporation
  • Neuronetics Inc.
  • Neuronetics Inc.
  • Functional Neuromodulation Ltd
  • Beijing PINS Medical Co., Ltd
  • Renishaw Plc

第12章 全球深部脑刺激器市场-DataM

简介目录
Product Code: DMMD2386

Market Overview

Deep Brain Stimulation Devices Market size was valued US$ 1.05 billion in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 8.4% during the forecast period (2022-2029).

Deep brain stimulation (DBS) devices are medical devices used in neurosurgical procedures to treat various neurological disorders. It works by sending the electrical impulses, through implanted electrodes, to the specific targets. It is implanted at one of the three brain sites, including the ventrointermedialis (VIM) nucleus of the thalamus, subthalamic nucleus (STN), and globus pallidus pars interna (GPi).

Market Dynamics

The rising R&D initiatives, rising demand for deep brain stimulation devices due to prevalence of neurological disorders, increased government funding and growing awareness towards these devices is driving the market's growth over the forecast period.

Increasing demand for deep brain stimulation products is expected to drive market growth.

The market is driven by the rising demand for deep brain stimulation products. The increase in the number of people undergoing deep brain stimulation (DBS) neurosurgical procedures and the increasing prevalence of neurological diseases, including epilepsy, Parkinson's disease, and other disorders. According to an Andres M. Lozano et al. 2019 study, published in the Nature Reviews Neurology Journal, around 160,000 patients have undergone Deep Brain Stimulation to treat neurological and non-neurological conditions worldwide, and expected to increase every year. Epilepsy is the most common neurological disease. According to the World Health Organization (WHO), approximately 50 million people have epilepsy worldwide. According to the Parkinson's Foundation, more than 10 million people have Parkinson's disease (PD) worldwide. It is more predominant among females in comparison to males.

The rise in the new product launch and approval shall stimulate market growth. For instance, in February 2019, Medtronic plc had launched Deep Brain Stimulation (DBS) for medically refractory epilepsy. It delivers the controlled electrical pulses to a brain target called the thalamus's anterior nucleus (ANT).

In January 2019, Boston Scientific Corporation had launched the Verse Primary Cell (PC) and Verse Gevia Deep Brain Stimulation (DBS) Systems featuring the Verse Cartesia Directional Lead. These systems feature the technology designed to allow physicians to control the range, shape, position, and direction of electrical stimulation to treat Parkinson's disease (PD) symptoms through highly-personalized therapy.

The market is witnessing technological advancement in the development of novel Deep Brain Stimulation products. For instance, In January 2020, Abbott Laboratories had received expanded clearance from the Food and Drug Administration (US FDA) for the Infinity Deep Brain Stimulation system to include the targeting of an area of the brain called the internal globus pallidus (GPi) that plays a vital role in in the motor function and can be targeted with DBS to improve the symptoms of Parkinson's disease not adequately controlled by medication. It is the only directional DBS system approved for all major targets used to treat movement disorders, Parkinson's disease, and essential tremors. It operates through an iOS software platform with Bluetooth wireless technology. It also allows the clinicians to streamline the programming process with an iPad mini device using Abbott's new Infirmity Programming feature to become more efficient in their practice and achieve optimal outcomes with directional leads. Moreover, this system allows the patients to manage their Infinity DBS System iPod touch controller symptoms.

High cost associated with deep brain stimulation devices is expected to hamper the market growth.

Factors such as the high cost of instruments and risk associated with stimulation devices are expected to hinder the market's growth over the forecast period.

Industry Analysis

The global deep brain stimulation devices market provides in-depth analysis of the market based on various industry factors such as Porter's Five Forces, Regulatory and Reimbursement Analysis, Supply Chain Analysis, Pricing Analysis, Unmet Needs.

Segment Analysis

Product type segment is expected to hold the largest market share in global deep brain stimulation devices market

The deep brain stimulation devices market is segmented on product type as a single-channel deep brain stimulator and dual-channel deep brain stimulator. The dual-channel deep brain stimulator segment accounts for the highest market share due to the high growth in deep brain stimulation devices' technological advancement with dual-channel deep brain stimulators. These devices are effective in simplifying the procedure for bilateral stimulation and enhancing the patient's comfort level. A one-sided dual-channel deep brain stimulator provides the stimulation of electrical pulses through two DBS leads. There is an increase in the number of companies developing dual-channel deep brain stimulator with technological advancement. For instance, Medtronic's Activa RC is a dual-channel, rechargeable neurostimulator for patients with high energy needs and has 15-year longevity. It delivers bilateral stimulation with a single device. It comprises the non-rechargeable battery and microelectronic circuitry to deliver a controlled electrical pulse to the brain's precisely targeted areas.

The single-channel deep brain stimulator segment is expected to have positive market growth over the forecasted period. The market is dominated by the availability of several single-channel deep brain stimulator devices. For instance, Medtronic's ActivaTM SC is a single-channel device with a daily maintenance-free battery that provides predictable longevity. It is the smallest non-rechargeable device in the Activa portfolio or deep brain stimulation. It is implanted in the chest or abdomen, connected to an extension, and leads implanted in the brain. It can be used to treat Parkinson's disease, Dystonia, obsessive-compulsive disorder (OCD), and suppression of tremors.

Further, the market is also classified based on the application as Parkinson's Disease, Epilepsy, Essential Tremor, Dystonia, Obsessive-Compulsive Disorder, and Others. The Parkinson's Disease segment accounts for the highest market share due to the higher adoption of deep brain stimulation (DBS) devices to treat Parkinson's Disease. It is recommended to treat patients with Parkinson's disease for at least four years and benefit from medications but have motor complications. There is an increase in the number of novel deep brain stimulation device approvals for the treatment of Parkinson's disease.

Geographical Analysis

North America region holds the largest market share in the global deep brain stimulation devices market

By region, the deep brain stimulation devices market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, North America dominated the deep brain stimulation devices market due to the increasing prevalence of Parkinson's Disease and Epilepsy. According to the Parkinson's Foundation, approximately 930,000 people are expected to be suffering from Parkinson's Disease by 2020. It is further expected that the prevalence of cases would increase and reach up to 1.2 million by 2030. According to the Centres for Disease Control and Prevention (CDC), around 3 million adults and 470,000 children and teens below 18 years have Epilepsy. The United States is expected to have the highest market share. There is high technological advancement, including deep brain stimulation devices with enhanced microelectrode designs, multi-target stimulation, integrated implantable pulse generators, robot-assisted implantation, etc. High healthcare expenditure for healthcare facilities & infrastructures shall stimulate market growth. The North America region is expected to maintain its dominant position over the forecasted period.

The Asia Pacific region is expected to have positive market growth due to the increased number of people undergoing Deep Brain Stimulation neurosurgical procedures. The growing burden for treating neurological diseases has led companies to develop cost-effective deep brain stimulation devices, especially in China, Australia, and Japan. There is growing awareness regarding the diagnosis, treatment, and management of neurological disorders such as epilepsy, essential tremors, Parkinson's disorder, etc. The increase in hospitals and neurology clinics will boost deep brain stimulation devices' demand over the forecasted period.

Competitive Landscape

The deep brain stimulation devices market is highly competitive with the presence of several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition. Boston Scientific Corporation., Aleva Neurotherapeutics SA, Medtronic Plc, Medtronic Plc, and Nevro Corporation

Abbott Laboratories, Aleva Neurotherapeutics SA, Boston Scientific Corporation, Medtronic Plc, NeuroPace Inc., Nevro Corporation, and Neuronetics Inc. are the leading market players with significant market share. In August 2019, Abbott Laboratories had expanded its deep brain stimulation (DBS) therapy by offering magnetic resonance (MR)-conditional labeling and innovative features.

In January 2020, Medtronic plc had received the European CE Mark approval for its deep brain stimulation device, i.e., Percept. It is the only Deep Brain Stimulation (DBS) system to be launched in the European Union (EU) with BrainSense technology that allows us to sense and record brain signals while delivering therapy to patients with neurologic disorders Parkinson's disease. BrainSense technology enables physicians to track patient-specific brain signals and correlate these with patient-recorded events, such as symptoms or side effects associated with their disease or the medications to treat it.

The companies are entering into collaborations, mergers, strategic partnerships, and acquisitions to increase the demand for deep brain stimulation devices and their expansion across the globe. For instance, in October 2019, GTX medical had merged with US-based medical device developer NeuroRecovery Technologies (NRT) to create a neurostimulation company focusing on spinal cord injury (SCI). The merged entity would be known as GTX medical BV that would focus on developing neuromodulation therapies to improve people's functional recovery with SCI.

Key Companies to Watch

Abbott Laboratories:

Overview: Abbott is American multinational company that develops medical devices and healthcare products. It was founded in 1888 and is headquartered in Illinois, United States. Their products and services include medical devices, diagnostics, nutritional products and branded generic medicines.

Product Portfolio:

Infinity DBS System: Infinity DBS is the first directional DBS system that has been approved for all key targets that are used for treatments like movement disorders, Parkinson's disease and Essential Tremor.

Key Developments: In July 2022, Abbott announced the Breakthrough Device Designation received grant from U.S. FDA for investigating its deep brain stimulation in TRD.

The global deep brain stimulation devices market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers:
      • 4.1.1.1. Increasing demand for deep brain stimulation products
    • 4.1.2. Restraints:
      • 4.1.2.1. High Cost associated with these devices
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Regulatory and Reimbursement Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Unmet Needs

6. By Product Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment
    • 6.1.2. Market Attractiveness Index, By Product Type Segment
  • 6.2. Single-Channel Deep Brain Stimulator
      • 6.2.1.1. Introduction
      • 6.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 6.3. Dual-Channel Deep Brain Stimulator

7. By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
    • 7.1.2. Market Attractiveness Index, By Application Segment
  • 7.2. Parkinson's Disease
      • 7.2.1.1. Introduction
      • 7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Epilepsy
  • 7.4. Essential Tremor
  • 7.5. Dystonia
  • 7.6. Obsessive-Compulsive Disorder
  • 7.7. Others

8. By End User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
    • 8.1.2. Market Attractiveness Index, By End User Segment
  • 8.2. Hospitals
      • 8.2.1.1. Introduction
      • 8.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Neurological Clinics
  • 8.4. Ambulatory Surgical Centers
  • 8.5. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Italy
      • 9.3.6.5. Spain
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. Australia
      • 9.5.6.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

  • 10.1. Key Developments and Strategies
  • 10.2. Company Share Analysis
  • 10.3. Product Types Benchmarking
  • 10.4. List of Key Companies to Watch

11. Company Profiles

  • 11.1. Abbott Laboratories
    • 11.1.1. Company Overview
    • 11.1.2. Product Type Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Aleva Neurotherapeutics SA
  • 11.3. Boston Scientific Corporation
  • 11.4. Medtronic Plc
  • 11.5. NeuroPace Inc.
  • 11.6. Nevro Corporation
  • 11.7. Neuronetics Inc.
  • 11.8. Neuronetics Inc.
  • 11.9. Functional Neuromodulation Ltd
  • 11.10. Beijing PINS Medical Co., Ltd
  • 11.11. Renishaw Plc

LIST NOT EXHAUSTIVE

12. Global Deep Brain Stimulation Devices Market - DataM

  • 12.1. Appendix
  • 12.2. About Us and End User
  • 12.3. Contact Us